VytlView is a business intelligence and data visualization platform designed to help health systems identify opportunities to optimize pharmacy revenue and operational performance. By analyzing
Host Lesley Pink talks with Maria Roberts (Director of Specialty Clinical Programs, VytlOne) and Alicia Morris (Director of Pharmacy & Clinical Operations, VytlOne) about VytlOne’s innovative approach to specialty
Patients initiating specialty medication therapy for complex rare disease face many challenges, including complex regimens and treatment tolerability considerations that can lead to early therapy
VytlAIQ enables health care providers to optimize 340B performance, reduce referral leakage, scale pharmacy operations, and improve patient outcomes and experience through AI-enabled pharmacy care.
The 340B Drug Pricing Program is vital for safety-net healthcare providers, allowing them to enhance access to medications, reduce medication costs for vulnerable populations, and
Oncology medicine spending is rising quickly. Over a five-year period, spending is expected to grow almost 75%. According to recent data, global spending on cancer medicines
Join our host, Lesley Pink, for our monthly podcast, The Strategic Dose, to learn from experts about breaking news, pharmacy and healthcare trends, and more. Listen
According to the FDA, a biosimilar is a biologic that is highly similar to another biologic that has been approved by the FDA. A biosimilar
Federal and state reform has shaped 340B developments this year. These developments could change how hospitals, health centers, and pharmacies manage drug pricing, eligibility, patient access, and cash flow. Below we
340B Leaders Upfront is your exclusive window into the industry leaders that provide products and services to hospitals, community health centers and other 340B providers
